Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
09 nov. 2023 07h30 HE
|
Verrica Pharmaceuticals Inc.
– Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – –...
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
25 oct. 2023 07h00 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
27 sept. 2023 08h00 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
31 août 2023 08h00 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
24 août 2023 08h30 HE
|
Verrica Pharmaceuticals Inc.
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children ...
Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum
23 août 2023 07h30 HE
|
Verrica Pharmaceuticals Inc.
Verrica’s product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States,...
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting
10 août 2023 16h05 HE
|
Verrica Pharmaceuticals Inc.
Presentation highlights the antitumor response of VP-315 for the non-surgical treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance There are...
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
08 août 2023 07h30 HE
|
Verrica Pharmaceuticals Inc.
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – ...
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
03 août 2023 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
26 juil. 2023 16h05 HE
|
Verrica Pharmaceuticals Inc.
– Verrica received $50M upon the close of the transaction; $75M of additional capital available in tranches based on the achievement of certain revenue milestones – – Proceeds from the transaction to...